Valuation dashboard for Annovis Bio, Inc. (ANVS) with P/E N/A, P/B -7.41, EV/EBITDA -0.82 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $1.04, ANVS has negative trailing earnings (P/E not meaningful) and an ROE of -6.86%. Market capitalisation stands at $44M.
Balance sheet quality for ANVS: current ratio of 5.8. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | -7.41 |
| EV / EBITDA | -0.82 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $0.84 |
| vs Current Price | -19.6% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ANVS | Annovis Bio, Inc. | $44M | -6.9% | ||
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $1.04 |
| Market Cap | $44M |
| Exchange | NYSE |
| Country | US |
Profitability
| Return on Equity | -685.96% |
| Return on Invested Capital | -400.40% |
| Return on Assets | -224.73% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ATNM · BCAB · BTAI · CELU · ELUT · EVAX · MAIA
Explore sector: Healthcare · Biotechnology
More sections of ANVS: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks